Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.52 |
| ▸ | PNMT | P11086 | 4/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | LOX | P28300 | 1/20 | 0.43 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26325920 | 0.85 | CSNK2A1 (0.49) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL17013472 | 0.85 | CSNK2A1 (0.52) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL15047147 | 0.85 | CSNK2A1 (0.47) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL5138176 | 0.85 | CSNK2A1 (0.62) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL8847353 | 0.81 | PNMT (0.50) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL29349576 | 0.80 | PNMT (0.67) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL112200 | 0.80 | PNMT (0.67) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL27755699 | 0.80 | PNMT (0.41) | CSNK2A1PNMTCSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL27806808 | 0.78 | PNMT (0.44) | CSNK2A1PNMTTAAR1 | |
| SCHEMBL4841378 | 0.78 | CA2 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018093695-A1 | FACTOR XIIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
| US-9410951-B2 | Method for producing substrate for making microarray | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9410951-B2 | Method for producing substrate for making microarray | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-09 | — | — | US | disclosed |
| CN-103226299-B | Electrophotographic image forming toner and developer | RICOH CO., LTD. (JP) | 2015-11-18 | — | — | CN | disclosed |
| CN-103309186-B | Toner, developer, handle box and image forming apparatus | RICOH CO., LTD. (JP) | 2015-09-30 | — | — | CN | disclosed |
| US-7964633-B2 | such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20100055337-A1 | Method for producing substrate for making microarray | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100055337-A1 | Method for producing substrate for making microarray | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2081889-A1 | SULFONAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080085928-A1 | Sulfonamide derivatives | HOFFMANN-LA ROCHE INC. | 2008-04-10 | — | — | US | disclosed |
| WO-2008037628-A1 | SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| EP-0007632-B1 | AROMATIC POLYAMIDE COMPOSITION | TEIJIN LIMITED (JP) | 1983-03-16 | — | — | EP | disclosed |
| EP-0007632-A1 | Aromatic polyamide composition | TEIJIN LIMITED (JP) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085928-A1 | Sulfonamide derivatives | SULT2A1, SULT1A1, SULT1E1 | CSNK2A1 939/4885PNMT 3569/4885CSNK2A2 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.